INTRODUCTION

Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms (LUTS) is common in older men. Medical treatment with alpha blocker is the first recommended option for patients with BPH/LUTS.1 Alpha blockers could improve BPH/LUTS by relaxing the prostatic urethra and bladder neck through alpha-receptor block.2 As a result of its prostate selectivity, tamsulosin may improve LUTS with fewer side effects.3 Many studies have shown that tamsulosin is effective and tolerated at doses of 0.2–0.8 mg once daily in patients with symptomatic BPH.3,5,7 In Asian countries, tamsulosin 0.2 mg has been widely used because of their relative low body mass index (BMI).5,7

Is Tamsulosin 0.2 mg Effective and Safe as a First-Line Treatment Compared with Other Alpha Blockers?: A Meta-Analysis and a Moderator Focused Study

Sung Ryul Shim1, Jae Heon Kim2, In Ho Chang3, In Soo Shin4, Sung Dong Hwang5, Khae Hwan Kim6, Sang Jin Yoon6, and Yun Seob Song2

1Institute for Clinical Molecular Biology Research, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul; 2Department of Urology, Soonchunhyang University College of Medicine, Seoul; 3Department of Urology, Chung-Ang University Hospital, Urological Science Institute, Chung-Ang University College of Medicine, Seoul; 4Department of Education, College of Education, Jeonju University, Jeonju; 5Department of Social Welfare, Kyungpook National University College of Social Science, Daegu; 6Department of Urology, Gil Hospital, Gachon University College of Medicine, Incheon, Korea.

Purpose: Tamsulosin 0.2 mg is used widely in Asian people, but the low dose has been studied less than tamsulosin 0.4 mg or other alpha blockers of standard dose. This study investigated the efficacy and safety of tamsulosin 0.2 mg by a meta-analysis and meta-regression.

Materials and Methods: We conducted a meta-analysis of efficacy of tamsulosin 0.2 mg using International Prostate Symptom Score (IPSS), maximal urinary flow rate (Qmax), post-voided residual volume (PVR), and quality of life (QoL). Safety was analyzed using adverse events. Relevant studies were searched using MEDLINE, EMBASE, and Cochrane library from January 1980 to June 2013.

Results: Ten studies were included with a total sample size of 1418 subjects [722 tamsulosin 0.2 mg group and 696 other alpha-blockers (terazosin, doxazosin, naftopidil, silodosin) group]. Study duration ranged from 4 to 24 weeks. The pooled overall standardized mean differences (SMD) in the mean change of IPSS from baseline for the tamsulosin group versus the control group was 0.02 [95% confidence interval (CI); -0.20, 0.25]. The pooled overall SMD in the mean change of QoL from baseline for the tamsulosin group versus the control group was 0.16 (95% CI; -0.16, 0.48). The regression analysis with the continuous variables (number of patients, study duration) revealed no significance in all outcomes as IPSS, QoL, and Qmax.

Conclusion: This study clarifies that tamsulosin 0.2 mg has similar efficacy and fewer adverse events compared with other alpha-blockers as an initial treatment strategy for men with lower urinary tract symptoms.

Key Words: Prostatic hyperplasia, alpha blockers, tamsulosin
tamsulosin has some adverse events including retrograde ejaculation and anejaculation. Considering that most of the adverse events are tolerable, abnormal ejaculation is significant because it increases the drug withdrawal rate. Abnormal ejaculation is a dose-related phenomenon. It is due to an emission, which is attributed to the alpha 1A receptor selectivity of seminal vesicle and vas deferens.

Several studies reported the efficacy and safety of tamsulosin 0.2 mg, but the results were varied, thus hampering any decision of whether to apply tamsulosin 0.2 mg as an initial treatment in real practice. Several studies reviewed the efficacy and safety of tamsulosin with or without meta-analysis, however, there have been no comparative studies on the tamsulosin 0.2 mg with other alpha blockers, especially including outcome measurement such as International Prostate Symptom Score (IPSS). Our previous study has focused on the improvement of LUTS by treatment with low-dose tamsulosin, however, it did not show the differences from other alpha blockers; the study merely described the overall improvement by tamsulosin 0.2 mg, and there were no controls for comparison.

The present study attempted to overcome the limitation of previous study and demonstrate the treatment efficacy and safety of tamsulosin 0.2 mg compared with other alpha-blockers. In addition, this is the first meta-analysis of tamsulosin 0.2 mg to evaluate the moderat or effects comparing with other alpha blockers.

MATERIALS AND METHODS

This systematic review and meta-analysis were guided by the standard Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol and also guided by the Cochrane Collaboration.

Searching strategy

A MEDLINE and Cochrane Collaboration search for studies from 1980 to 2013 were selected using electronic database search formula: Search ((((((“Lower Urinary Tract Symptoms” [Mesh]) OR “lower urinary tract symptom” [tiabkw]) OR “LUTS” [tiabkw]) OR “Prostatic hyperplasia” [Mesh]) OR “benign prostatic hyperplasia” [tiabkw]) OR “BPH” [tiabkw])) AND (((“tamsulosin” [Supplementary Concept]) OR “tamsulosin” [tiabkw]) OR “YM178” [all]). Same electronic database search formula using Emtree was adopted for EMBASE search. Screening criteria were comparison (adrenergic alpha-1 receptor antagonists), outcome (IPSS), and article type (randomized controlled trial) without language restrictions.

Study selection

The studies were included if they met the following criteria: 1) reported outcome measurements included IPSS, 2) interventions included administration of tamsulosin and other alpha-blockers, 3) participants included BPH, and 4) reasonable intention-to-treat (ITT) analysis was performed in randomized controlled trials (RCTs). Two authors (SR Shim and JH Kim) reviewed all filtered articles with title and abstract using predefined inclusion and exclusion criteria. Final inclusion was determined by the GRADE Working Group. References and data for each included study were carefully cross checked to ensure no over lapping data was presented and to maintain the meta-analysis integrity.

Types of interventions and outcomes

The experimental group received tamsulosin 0.2 mg and the control group orally received other standard dose of alpha-blockers (terazosin, doxazosin, naftopidil, silodosin). Outcomes measured mean changes of IPSS, quality of life (QoL), maximal urinary flow rate (Qmax), and post-voided residual volume (PVR) from baseline in patients receiving tamsulosin versus patients receiving other alpha-blockers. Adverse events measured the proportional differences between the tamsulosin group and the other alpha-blockers group.

Types of moderators

Earlier studies have differed in a number of parameters such as countries, control agents, the number of patients, and study duration. We now elaborated on how differences in some of these moderators affect outcomes.

Quality assessment

The risk of bias and methodological quality were assessed in duplicate using the Cochrane Collaboration tool. We evaluated the following six parameters: 1) random sequence generation, 2) allocation concealment, 3) blinding of caregivers, personnel, and outcome assessors, 4) incomplete outcome data, 5) selective outcome reporting, and 6) other bias. We graded each parameter of trial quality as low risk of bias, unclear risk of bias, and high risk of bias, and conducted an overall assessment for each controlled trial using the same three criteria. The quality of the evidence related to the estimation of benefits and disadvantages in the population followed the suggestions of the GRADE Working Group by adopting the use of Grade Pro software 3.6.

Meta-analysis assessment of outcome findings and statistical analysis

All variables used the same measurement units and outcomes were recorded as continuous data. The primary outcome was change in LUTS measured by IPSS. Secondary measures included QoL, Qmax, PVR, and adverse events. In the study without standard deviation, the estimate of the pooled standard deviation of the two groups (before/after) was applied. Standardized mean differences (SMD, Hedges’ g, the difference between experimental and control group pooled mean change) along with their 95% confidence intervals (CIs) were calculat-
ed for continuous variables. Random-effects model of DerSimonian and Laird were conducted to obtain pooled overall SMD and 95% CIs for outcomes.

Meta-ANOVA or meta-regression analysis was conducted for each moderator. To examine potential moderators, we used the meta-analytic mixed effects model (MEM). We analyzed the variability in the effect sizes due to differences between the categorical moderators (e.g., countries and control agents) with a weighted meta-analytic analogue to the analysis of variance. For continuous moderators (e.g., number of patients and study duration), we used a restricted maximum likelihood (REML) estimator of the variance of the true effects. However, we didn’t analyze moderator effects of post-voided residual urine due to insufficient observations and also we excluded the moderator if there was one observation in each category. The above mentioned analyses were conducted with Comprehensive Meta-Analysis version 2.2 software (Biostat, Englewood, NJ, USA) and STATA version 11.2 software (Stata Corp LP, College Station, TX, USA). SPSS version 21.0 software (IBM, New York, NY, USA) was used to perform the chi-squared-test.

Assessment of potential publication bias
Publication bias was explained by Funnel plot of this meta-analysis using standard error as the measure of study size and ratio measures of treatment effect. Asymmetry findings in funnel plots indicate publication bias, but the shape of the plot in the absence of bias depends on the choice of axes.

RESULTS
Inclusion of studies
The initial search identified a total of 2862 articles from the electronic database (PubMed: n=722, Cochrane: n=129, Embase: n=2011). After exclusion of 690 studies containing overlapping data or appearing in more than one database and after screening the titles and abstracts, 2026 studies that did not meet the inclusion criteria were further excluded. After intensive screening by detailed evaluation of 146 studies, a total of 21 studies were found to be eligible. Of these, 11 were excluded due to not using low-dose (0.2 mg) tamsulosin in the experimental group (n=5), not using alpha blocker in control group (n=4), and outcome value discordance (n=2). Finally, 10 studies that met all inclusion criteria were included. The 10 studies consisted of 1418 subjects (722 experimental group and 696 control group). A detailed flow chart showing the selection process is shown in Fig. 1. A systematic review of 10 studies was conducted on the detailed experimental differences and subject descriptions (doxazosin 4 mg, one study; terazosin 5 mg, one study; terazosin 2 mg, two studies; silodosin 8 mg, two studies; naftopidil 25 mg, one study; naftopidil 50 mg, three studies) (Table 1). The duration of treatment ranged

![Fig. 1. Flowchart of the study selection process. BPH, benign prostatic hyperplasia; LUTS, lower urinary tract symptoms; IPSS, International Prostate Symptom Score.](http://dx.doi.org/10.3349/ymj.2016.57.2.407)
| Study | Subjects for analysis (Drug or procedure) | IPSS, QoL, Qmax, PVR | Inclusion criteria | Quality of the evidence (grade) |
|-------|----------------------------------------|---------------------|------------------|-------------------------------|
| Na, et al. | Chinese men (mean age 68.5 yrs, symptomatic BPH) 104/97 | Tamsulosin (0.2 mg qd)/terazosin (2 mg qd) 6 wks (2 wks for wash out and 4 wks for treatment) | IPSS >13, Qmax >15 mL/s, AR >15 mL/s nocturia once or more per night | Moderate |
| Zhang, et al. | Chinese men (mean age 68.6 yrs, symptomatic BPH) 95/94 | Tamsulosin (0.2 mg qd)/doxazosin (4 mg qd) 10 wks (2 wks for screening and 8 wks for treatment) | IPSS ≥8, QoL, Qmax ≤15 mL/s on full bladder, nocturia ≥3 per night | Low |
| Ju, et al. | Chinese men (mean age 65.9 yrs, symptomatic BPH) 38/39 | Tamsulosin (0.2 mg qd)/naftopidil (25 mg qd) 6 wks | IPSS ≥13, Qmax <12 mL/s, voided volume >100 mL, prostate volume ≥20 mL | Moderate |
| Yu, et al. | Taiwanese men (mean age 66.3 yrs, symptomatic BPH) 83/87 | Tamsulosin (0.2 mg qd) plus placebo qd/silodosin (4 mg bid) 14 wks (2 wks for screening and 12 wks for treatment) | IPSS ≥8, QoL ≥3, Qmax ≤15 mL/s, QoL score of ≥3, PVR ≤150 mL, total voided volume ≥20 mL | Moderate |
| Kawabe, et al. | Japanese men (mean age 65.6 yrs, symptomatic BPH) 192/175/89 | Tamsulosin (0.2 mg qd)/silodosin (4 mg bid) plus placebo qd/terazosin (4 mg bid) 14 wks (2 wks for screening and 12 wks for treatment) | IPSS ≥8, QoL ≥3, Qmax ≤15 mL/s, QoL score of ≥3, PVR ≤150 mL, total voided volume ≥20 mL | Moderate |
| Okada, et al. | Japanese men (mean age 65.7 yrs, symptomatic BPH) 65.7 | Terazosin (1 mg qd) or naftopidil (25 mg bid) followed by naftopidil (50 mg bid) 12 wks | IPSS ≥8, QoL ≥3, Qmax ≤15 mL/s, QoL score of ≥3, PVR ≤150 mL, total voided volume ≥20 mL | Moderate |
| Gotch, et al. | Japanese men (mean age 69.3 yrs, symptomatic BPH) 29/28 | Terazosin (1 mg bid) or naftopidil (25 mg bid) followed by naftopidil (50 mg bid) 12 wks | IPSS ≥8, QoL ≥3, Qmax ≤15 mL/s, QoL score of ≥3, PVR ≤150 mL, total voided volume ≥20 mL | Moderate |
| Masumori, et al. | Japanese men (mean age 64.9 yrs, symptomatic BPH) 35/36 | Terazosin (1 mg bid) or naftopidil (25 mg bid) followed by naftopidil (50 mg bid) 12 wks | IPSS ≥8, QoL ≥3, Qmax ≤15 mL/s, QoL score of ≥3, PVR ≤150 mL, total voided volume ≥20 mL | Moderate |
| Hanyu, et al. | Japanese men (mean age 70.7 yrs, symptomatic BPH) 75/69 | Terazosin (1 mg bid) or naftopidil (25 mg bid) followed by naftopidil (50 mg bid) 12 wks | IPSS ≥8, QoL ≥3, Qmax ≤15 mL/s, QoL score of ≥3, PVR ≤150 mL, total voided volume ≥20 mL | Moderate |

**Table 1. Randomized Trials of Tamsulosin 0.2 mg for BPH**
| Study                   | Random sequence generation (selection bias) | Allocation concealment (selection bias) | Blinding of participants and personnel (performance bias) | Blinding of outcome assessment (detection bias) | Incomplete outcome data (attrition bias) | Selective reporting (reporting bias) | Other bias |
|-------------------------|---------------------------------------------|----------------------------------------|-----------------------------------------------------------|-----------------------------------------------|---------------------------------------|-------------------------------------|------------|
| Na, et al.⁶              | "randomized"                                | Unclear                                | Described "patients were single-blind"                    | Low risk (almost patients of analysis set were completed) | Low risk (almost patients of analysis set were completed) | Unclear                             | Low risk   |
| Zhang, et al.¹²          | "randomized"                                | Unclear                                | Unclear                                                   | Unclear                                       | Unclear                               | Low risk (almost patients of analysis set were completed) | Low risk   |
| Ju, et al.²²             | "randomized"                                | Unclear                                | Described "double-blinding"                               | Overally assumed ITT analysis using whole sample set, and low dropout rate (3.8%) | Low risk (almost patients of analysis set were completed) | Unclear                             | Low risk   |
| Yu, et al.²²             | "randomized"                                | Unclear                                | Described "double-blinding"                               | Overally assumed ITT analysis using whole sample set, and low dropout rate (0.2%) | Low risk (almost patients of analysis set were completed) | Unclear                             | Low risk   |
| Kawabe, et al.²³         | "randomized"                                | Unclear                                | Described "double-blinding"                               | Overally assumed ITT analysis using whole sample set, and low dropout rate (0.2%) | Low risk (almost patients of analysis set were completed) | Unclear                             | Low risk   |
| Okada, et al.²⁵          | "randomized"                                | Unclear                                | Described "single-blind"                                  | Overally assumed ITT analysis using whole sample set, and low dropout rate (3.2%) | Low risk (almost patients of analysis set were completed) | Unclear                             | Low risk   |
| Gotoh, et al.²⁰          | "randomized"                                | Unclear                                | "single-blind"                                            | Low risk (almost patients of analysis set were completed) | Low risk (almost patients of analysis set were completed) | Unclear                             | Low risk   |
| Masumori, et al.²⁴       | "randomized"                                | Unclear                                | "single-blind"                                            | Low risk (almost patients of analysis set were completed) | Low risk (almost patients of analysis set were completed) | Unclear                             | Low risk   |
| Hanyu, et al.²¹          | "randomized"                                | Unclear                                | "single-blind"                                            | Low risk (almost patients of analysis set were completed) | Low risk (almost patients of analysis set were completed) | Unclear                             | Low risk   |
| Lee and Lee²             | "randomized"                                | Unclear                                | "single-blind"                                            | Low risk (almost patients of analysis set were completed) | Low risk (almost patients of analysis set were completed) | Unclear                             | Low risk   |

ITT, intention-to-treat. Dropout rate due to adverse events of treatment.
from 4–12 weeks. The language of included studies were English, Chinese, and Japanese.

Quality assessment
Two authors (SR Shim and JH Kim) critically appraised the selected studies using critical criteria of Cochrane Collaboration. Table 2 shows the quality assessment and characteristics of the included studies. All of the studies described randomized methods and reasonable ITT analysis. One study included allocation concealment. Blinding methods were conducted as single-blind in three studies and double-blind in three studies. After rating of each item of the critical appraisal, allocation concealment, blinding method, and detection bias resulted in a moderate grade.

Outcome findings

**IPSS**
Ten studies (n=1418; 722 experimental group and 696 control group) reported detailed data on IPSS. The pooled overall SMD in the mean change of IPSS from baseline for the tamsulosin group versus the control group was 0.02 (95% CI; -0.20, 0.25). There was no statistical difference between groups. Heterogeneity test produced p<0.01 and the Higgins’ I² was 75.9%. For evaluation of control agents that have an impact on the improvement of BPH, we also conducted subgroup analysis. The SMD changes of IPSS for the tamsulosin group versus the control group were -0.15 (95% CI; -0.43, 0.13) in terazosin 2 mg, 0.21 (95% CI; 0.04, 0.38) in silodosin 8 mg, and -0.30 (95% CI; -0.68, 0.09) in naftopidil 50 mg (Fig. 2).

**QoL**
Seven studies (n=1068; 541 experimental group and 527 control group) reported detailed data on QoL. The pooled overall SMD in the mean change of QoL from baseline for the tamsulosin group versus the control group was 0.16 (95% CI; -0.16, 0.48). There was no statistical difference between groups. Heterogeneity test produced p<0.01 and the Higgins’ I² was 83.8%. For evaluation of control agents that have an impact on the improvement of BPH, we also conducted subgroup analysis. The SMD changes of QoL for the tamsulosin group versus the control group were 0.21 (95% CI; 0.04, 0.38) in silodosin 8 mg, and -0.11 (95% CI; -0.57, 0.35) in naftopidil 50 mg (Fig. 3).

**Qmax**
Ten studies (n=1418; 722 experimental group and 696 control group) reported detailed data on Qmax. The pooled overall SMD in the mean change of Qmax from baseline for the tamsulosin group versus the control group was 0.00 (95% CI; -0.16, 0.16). There was no statistical difference between groups. Heterogeneity test produced p=0.03 and the Higgins’ I² was 51.2%. For evaluation of control agents that have an impact on the improvement of BPH, we also conducted subgroup analysis. The SMD changes of Qmax for the tamsulosin group versus the control group were 0.02 (95% CI; -0.28, 0.32) in terazosin 2 mg, 0.22 (95% CI; 0.05, 0.39) in silodosin 8 mg, and 0.02 (95% CI; -0.21, 0.26) in naftopidil 50 mg (Fig. 4).

**PVR**
Four studies (n=474; 237 experimental group and 237 control group) reported detailed data on PVR. The pooled overall SMD in the mean change of PVR from baseline for the tamsulosin group versus the control group was 0.00 (95% CI; -0.16, 0.16). There was no statistical difference between groups.

---

**Table 2.** Statistics for each study

| Study                  | Control       | Tamsulosin Means (95% CI) | Control Means (95% CI) | SMD  | Lower limit | Upper limit |
|------------------------|---------------|---------------------------|------------------------|------|-------------|-------------|
| Zhang, et al.12         | Doxazosin 4 mg| 95  -7.40  4.16           | 94  -10.20  4.77   | 0.62 | 0.33        | 0.92        |
| Lee and Lee4            | Terazosin 5 mg| 39  -6.40  7.00           | 33  -8.00  7.20   | 0.22 | -0.24       | 0.69        |
| Na, et al.6             | Terazosin 2 mg| 104 -9.70  6.00           | 97  -8.50  5.45   | -0.24 | -0.52       | 0.04        |
| Okada, et al.26         | Terazosin 2 mg| 29  -8.10  7.25           | 28  -8.70  6.25   | 0.09 | -0.43       | 0.61        |
| Subtotal (terazosin 2 mg)|              |                           |                        | -0.15 | -0.43       | 0.13        |
| Yu, et al.26            | Silodosin 8 mg| 83  -10.00  5.10          | 87  -10.60  5.10   | 0.12 | -0.18       | 0.42        |
| Kawabe, et al.23        | Silodosin 8 mg| 192 -6.80  5.70           | 175 -8.30  6.40   | 0.25 | 0.04        | 0.45        |
| Subtotal (silodosin 8 mg)|              |                           |                        | 0.21 | 0.04        | 0.38        |
| Ju, et al.22            | Naftopidil 25 mg| 38  -9.21  4.53          | 39  -8.82  4.47   | -0.09 | -0.53       | 0.36        |
| Gotoh, et al.23         | Naftopidil 50 mg| 75  -8.40  7.07          | 69  -5.90  5.93   | -0.38 | -0.71       | -0.05       |
| Masumori, et al.24      | Naftopidil 50 mg| 35  -7.20  6.10          | 38  -3.80  5.10   | -0.60 | -1.07       | -0.13       |
| Hanju, et al.27         | Naftopidil 50 mg| 32  -5.30  4.90          | 36  -6.10  7.20   | 0.13 | -0.35       | 0.60        |
| Subtotal (naftopidil 50 mg)|               |                           |                        | -0.30 | -0.68       | 0.09        |
| Overall                 |               |                           |                        | 0.02 | -0.20       | 0.25        |

---

**Fig. 2.** Forest plot diagram showing the effect of tamsulosin 0.2 mg on International Prostate Symptom Score. SDM, standardized mean difference; CI, confidence interval.
| Study            | Control          | Tamsulosin | Control | SMD  | Lower limit | Upper limit |
|------------------|------------------|------------|---------|------|-------------|-------------|
| Zhang, et al.12  | Doxazosin 4 mg   | 95         | 94      | -1.30| 0.80        | 0.94        | 1.24        |
| Okada, et al.23  | Terazosin 2 mg   | 29         | 28      | -0.90| 1.27        | 0.00        | 0.52        |
| Yu, et al.26     | Silodosin 8 mg   | 83         | 87      | -1.20| 1.10        | 0.18        | 0.48        |
| Kawabe, et al.25 | Silodosin 8 mg   | 192        | 175     | -1.40| 1.30        | 0.22        | 0.43        |
| Subtotal         | (silodosin 8 mg) |            |         |      |             |             |             |
| Gotoh, et al.20  | Naftopidil 50 mg | 75         | 69      | -1.40| 1.33        | -0.07       | 0.26        |
| Masumori, et al.24 | Naftopidil 50 mg | 35        | 38      | -1.90| 1.80        | -0.59       | -0.12       |
| Hanyu, et al.21  | Naftopidil 50 mg | 32         | 36      | -1.40| 0.90        | 0.32        | 0.79        |
| Subtotal         | (naftopidil 50 mg) |          |         |      |             |             |             |
| Overall          |                  |            |         |      |             |             |             |

**Fig. 3.** Forest plot diagram showing the effect of tamsulosin 0.2 mg on quality of life. SDM, standardized mean difference; CI, confidence interval.

| Study            | Control          | Tamsulosin | Control | SMD  | Lower limit | Upper limit |
|------------------|------------------|------------|---------|------|-------------|-------------|
| Zhang, et al.12  | Doxazosin 4 mg   | 95         | 94      | -13.80| 29.86       | 0.21        | 0.07        | 0.50        |
| Gotoh, et al.20  | Naftopidil 50 mg | 75         | 69      | -9.60 | 46.39       | 0.08        | 0.25        | 0.40        |
| Masumori, et al.24 | Naftopidil 50 mg | 35        | 38      | -1.10 | 77.20       | 0.04        | 0.42        | 0.50        |
| Hanyu, et al.21  | Naftopidil 50 mg | 32         | 36      | -5.20 | 17.40       | 0.28        | 0.22        | 0.73        |
| Overall          |                  |            |         |      |             |             |             |

**Fig. 4.** Forest plot diagram showing the effect of tamsulosin 0.2 mg on maximal urinary flow rate. SDM, standardized mean difference; CI, confidence interval.

| Study            | Control          | Tamsulosin | Control | SMD  | Lower limit | Upper limit |
|------------------|------------------|------------|---------|------|-------------|-------------|
| Zhang, et al.12  | Doxazosin 4 mg   | 95         | 94      | -19.50| 22.68       | 0.21        | 0.07        | 0.50        |
| Gotoh, et al.20  | Naftopidil 50 mg | 75         | 69      | -13.60| 55.94       | 0.08        | 0.25        | 0.40        |
| Masumori, et al.24 | Naftopidil 50 mg | 35        | 38      | -4.30 | 69.80       | 0.04        | 0.42        | 0.50        |
| Hanyu, et al.21  | Naftopidil 50 mg | 32         | 36      | -11.80| 31.00       | 0.26        | 0.22        | 0.73        |
| Overall          |                  |            |         |      |             |             |             |

**Fig. 5.** Forest plot diagram showing the effect of tamsulosin 0.2 mg on post-voided residual volume. SDM, standardized mean difference; CI, confidence interval.

http://dx.doi.org/10.3349/ymj.2016.57.2.407
tamsulosin group versus the control group was 0.15 (95% CI; -0.03, 0.33). There was no statistical difference between groups (Fig. 5).

Moderator analyses
Table 3 provides an overview of the moderator analyses. The regression analysis with the continuous variables (number of patients, study duration) revealed no significance in all outcomes as IPSS, QoL, and Qmax. With respect to study duration, there were slightly higher effect sizes in tamsulosin with IPSS and Qmax than control groups (Fig. 6). However, the differences were not significant in IPSS and Qmax ($p=0.832$ and 0.265, respectively). Subgroup analysis for the pooled IPSS, QoL, and Qmax was performed according to country and control agent. In particular, it was performed for the control group which included more than two studies in each category. The results of meta-ANOVA were not statistically significant in all outcomes. With respect to country, the SMD in China of QoL was 0.559 (95% CI; 0.040, 1.077) and it was in favor of control than tamsulosin. However, it didn’t show the difference in the category ($p=0.074$). With respect to control agent, the SMD in silodosin of Qmax was 0.219 (95% CI; 0.050, 0.389) and it was in favor of tamsulosin than control. However, it didn’t show the difference in the category ($p=0.127$).

Safety
Three of the 10 studies did not describe adverse events.12,21,22 The remaining seven studies6,14,20,23-26 described the adverse events including urogenital system, circulatory system, digestive system, nervous system, respiratory system, dermatic system, and others. Although not all studies mentioned specific adverse events, tamsulosin was generally well tolerated and had a lower rate of adverse events, especially compared with terazosin (Table 4). Tamsulosin versus silodosin was described in two studies.23,26 Adverse events were reported in 52.4% (144/275) of the tamsulosin group and 70.2% (184/262) of the silodosin group. The differences were statistically significant ($p<0.001$). In more detailed analysis, the tamsulosin group showed high rhinitis value and the silodosin group showed high values of abnormal ejaculation, dry mouth, and loose stool. All were statistically significant. Tamsulosin versus naftopidil was described in two studies.23,24 The incidence of adverse events was not significantly different ($p=0.933$). Tamsulosin versus terazosin was described in three studies.6,14,25 Adverse events were reported in 8.7% (15/172) of the tamsulosin group and 50.0% (79/158) of the terazosin group. The differences were statistically significant ($p<0.001$). In more detailed analysis, the terazosin group showed higher values of orthostatic hypotension, headache, dizziness, dyspepsia, and dry mouth than the tamsulosin group. All were statistically significant.
Publication bias

The Funnel plot to detect the publication bias or small-study effect in the included studies is summarized in Fig. 7. In the IPSS analysis, three studies lay to the left and one study lay to the right of the funnel. Individual studies are distributed symmetrically about the combined effect size and toward the top of the graph. Thus, there was no evidence of publication bias in this meta-analysis.

DISCUSSION

Transurethral prostatectomy has traditionally been regarded as the most effective method, but most patients prefer medical treatment.27 Currently, the efficacy and tolerability of alpha-1 adrenergic blocker are of great interest and regarded as the first-line treatment for treating BPH/LUTS.28 Among the currently available alpha 1 adrenergic blockers (terazosin, doxazosin, alfuzosin, and tamsulosin), tamsulosin is one of the most commonly used alpha blocker due to its well-known efficacy and safety.29 Tamsulosin is known to have less descending effect of blood pressure compared with other non-selective alpha blockers.30,31

An initial study by Abrams, et al.32 showed the efficacy and safety of tamsulosin and suggested the optimum dosage of tamsulosin as 0.4 mg. The standard treatment dosage of tamsulosin in clinical practice in Western countries starts from 0.4 mg/day. However, tamsulosin 0.2 mg as an initial treatment has also been found to be effective in several studies in Asian countries.3,5,7 The main reason is the relatively lower BMI of Asian men than Western men. East Asian males, especially Korean, Japanese, and Chinese, have smaller BMIs than Western men, and initial tamsulosin 0.2 mg was set because of expected adverse effects if the same dose used in Western men was adopted. Previous studies with standard dose of tamsulosin showed that the total IPSS score was improved by 36.2% and the Qmax by 13.7% compared with baseline.32–36 Long-term safety and efficacy of tamsulosin 0.4 mg/day were also demonstrated.36

In our meta-analysis, the improvements of IPSS, QoL, Qmax, and PVR were similar to other alpha-blockers; thus, tamsulosin 0.4 mg and also tamsulosin 0.2 mg are suitable for initial treatment strategy, especially in Asians.

Another merit of tamsulosin 0.2 mg is the lower rate of adverse events. Although most adverse events associated with alpha 1 blockers, especially compared with terazosin, are generally mild and well-tolerated, retrograde ejaculation is an important reason for patient withdrawal. The prevalence of retrograde ejaculation by tamsulosin is known to be about 7%.37 Several reports showed favorable outcome of retrograde ejaculation during intermittent tamsulosin treatment.38,39 Giuliano8 reported that tamsulosin 0.8 mg decreased mean ejaculatory volume in almost 90% of men while no ejaculation was noted in 35% of men. This ejaculatory side effect is related with the dose of tamsulosin. This is also a reasonable ground for recommending tamsulosin 0.2 mg as a first-line treatment unless the efficacy of tamsulosin 0.2 mg is not inferior to other standard dose of alpha blockers.

Although retrograde ejaculation is a weak point of tamsulosin, a recent large retrospective study described the benefit of taking tamsulosin to improve sexual function in which erectile function was best preserved in men treated with tamsulosin, compared with not taking tamsulosin.40 This abnormal ejaculation is related with the dose of tamsulosin. This is also a reasonable ground for recommending tamsulosin 0.2 mg as a first-line treatment.

To the best of our knowledge, this study is the first scientific reviews about tamsulosin 0.2 mg for BPH/LUTS as an initial treatment strategy to investigate, comparing the efficacy and safety with other alpha blockers. Our prior study has investigated the general effect of tamsulosin 0.2 mg using single arm analysis.15 Using analysis with moderation including meta-regression and meta-ANOVA, we could overcome the heterogeneity of control including different types of alpha blockers. Moreover, the objective analysis of IPSS is the most prominent feature of our study.

http://dx.doi.org/10.3349/ymj.2016.57.2.407

Fig. 6. Meta-regression analysis of IPSS & Qmax vs. study duration. IPSS, International Prostate Symptom Score; Qmax, maximal urinary flow rate.
Limitations of this meta-analysis reflect common limitations of other systematic reviews and meta-analyses. Indirect evidence should be cautiously applied in practice as it is usually considered less reliable than direct evidence. However, in the present study, two sets of controlled trials were sufficiently similar in terms of moderators of relative treatment effect, which enabled scientific indirect analysis with moderation. These systematic reviews and meta-analyses could not overcome the bias of the original studies. Moreover, they were themselves influenced by selection bias and publication bias. For instance, four trials in the present study were laid out of the funnel plot, indicating publication bias. However, Sutton et al. reviewed 48 articles from Cochrane Database of Systematic Reviews and showed publication or related biases were common in the investigation of meta-analyses. Moreover, they found that these biases did not affect the conclusions in most cases.

Our meta-analysis focused on the comparison between tamsulosin 0.2 mg and other alpha blockers as an initial treatment option. Although we performed a subgroup analysis with limited circumstance due to small number of studies for each subgroup, all other alpha-blockers were compared as controls. This was reasonable for the initial hypothesis of our study. To control the heterogeneity of control groups, we implemented

\[
\begin{array}{|c|c|c|c|c|}
\hline
\text{Adverse events} & \text{Tamsulosin} & \text{Control} & \text{No. studies} & \text{p value} \\
\hline
\text{Vs. silodosin:} & & & & \\
\text{Any adverse event} & 144/275 & 52.4 & 184/262 & 70.2 & <0.001* \text{ vs. silodosin} \\
\text{Rhinitis} & 53/275 & 19.3 & 33/262 & 12.6 & 0.035* \\
\text{Diarrhea} & 13/275 & 4.7 & 12/262 & 4.6 & 0.936 \\
\text{Dizziness} & 16/275 & 5.8 & 16/262 & 6.1 & 0.888 \\
\text{Abnormal ejaculation} & 11/275 & 4.0 & 48/262 & 18.3 & <0.001* \\
\text{Dry mouth} & 7/275 & 2.5 & 18/262 & 6.9 & 0.017* \\
\text{Urinary incontinence} & 11/275 & 4.0 & 11/262 & 4.2 & 0.908 \\
\text{Loose stool} & 7/275 & 2.5 & 16/262 & 6.1 & 0.042* \\
\hline
\text{Vs. naftopidil:} & & & & \\
\text{Any adverse event} & 15/110 & 13.6 & 15/107 & 14.0 & 0.935 \\
\text{Headache} & 2/110 & 1.8 & 1/107 & 0.9 & 1.000 \\
\text{Diarrhea} & 1/110 & 0.9 & 1/107 & 0.9 & 1.000 \\
\text{Abdominal distention} & 0/110 & 0.0 & 1/107 & 0.9 & 0.493 \\
\text{Dizziness} & 5/110 & 4.5 & 1/107 & 0.9 & 0.212 \\
\text{Orthostatic hypotension} & 1/110 & 0.9 & 2/107 & 1.9 & 0.618 \\
\text{Abnormal ejaculation} & 4/110 & 3.6 & 2/107 & 1.9 & 0.683 \\
\text{Rash} & 0/110 & 0.0 & 1/107 & 0.9 & 0.493 \\
\text{Urinary incontinence} & 1/110 & 0.9 & 0/107 & 0.0 & 0.935 \\
\text{Vertigo} & 1/110 & 0.9 & 0/107 & 0.0 & 1.000 \\
\text{Sleepiness} & 0/110 & 0.0 & 1/107 & 0.9 & 0.493 \\
\text{Numbness tongue} & 0/110 & 0.0 & 4/107 & 3.7 & 0.057 \\
\text{Unsteady gait} & 0/110 & 0.0 & 1/107 & 0.9 & 0.493 \\
\hline
\text{Vs. terazosin:} & & & & \\
\text{Any adverse event} & 15/172 & 8.7 & 79/158 & 50.0 & <0.001* \\
\text{Headache} & 1/172 & 0.6 & 7/158 & 4.4 & 0.030† \\
\text{Constipation} & 0/172 & 0.0 & 4/158 & 2.5 & 0.052 \\
\text{Abdominal distention} & 1/172 & 0.6 & 0/158 & 0.0 & 1.000 \\
\text{Dyspepsia} & 0/172 & 0.0 & 5/158 & 3.2 & 0.024† \\
\text{Dizziness} & 10/172 & 5.8 & 41/158 & 25.9 & <0.001* \\
\text{Orthostatic hypotension} & 1/172 & 0.6 & 10/158 & 6.3 & 0.004* \\
\text{Rash} & 1/172 & 0.6 & 1/158 & 0.6 & 1.000 \\
\text{Pruritus} & 1/172 & 0.6 & 1/158 & 0.6 & 1.000 \\
\text{Dry mouth} & 0/172 & 0.0 & 8/158 & 5.1 & 0.003† \\
\text{Palpitation} & 0/172 & 0.0 & 2/158 & 1.3 & 0.228 \\
\hline
\end{array}
\]

\*Statistically significant differences between categories with same footnote symbol using χ²-test. †Statistically significant differences between categories with same footnote symbol using Fisher's exact test.
sulosin 0.2 mg could be widened. Considering dose-related adverse events, the indication for tamsulosin 0.2 mg for first-line treatment is advocated.

Overview of tamsulosin 0.2 mg provides more scientific evidence of efficacy and safety of tamsulosin 0.2 mg, and also the meta-regression method to identify the moderator’s effect. By this meta-analysis and meta-regressions, we could clarify the efficacy of tamsulosin 0.2 mg compared with other alpha blockers with standard doses.

Although social-demographic factors such as income and extent of education could affect the treatment pattern and outcome in BPH,44 we did not include those factors because of the widened heterogeneity and missing data. However, this overview of tamsulosin 0.2 mg provides more scientific evidence of efficacy and safety of tamsulosin 0.2 mg, and also advocates the use of tamsulosin 0.2 mg for first-line treatment.

In conclusion, tamsulosin 0.2 mg is efficacious, with improvements of IPSS, QoL, Qmax, and PVR. Tamsulosin 0.2 mg is suitable as an initial treatment for symptomatic BPH. Considering dose-related adverse events, the indication for tamsulosin 0.2 mg could be widened.

ACKNOWLEDGEMENTS

This work was supported in part by the Soonchunhyang University Research Fund.

REFERENCES

1. Chapple CR. BPH Disease Management. Introduction and concluding remarks. Eur Urol 1999;36 Suppl 3:1-6.
2. Djavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004;64:1081-8.
3. Lee E. Comparison of tamsulosin and finasteride for lower urinary tract symptoms associated with benign prostatic hyperplasia in Korean patients. J Int Med Res 2002;30:584-90.
4. Lee E, Lee C. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 1997;80:606-11.
5. Li NC, Chen S, Yang XH, Du LD, Wang JY, Na YQ; Beijing Tamsulosin Study Group. Efficacy of low-dose tamsulosin in Chinese patients with symptomatic benign prostatic hyperplasia. Clin Drug Investig 2003;23:781-7.
6. Na YJ, Guo YL, Gu FL. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. J Med 1998;29:289-304.
7. Park CH, Chang HS, Oh BR, Kim HJ, Sul CK, Chung SK, et al. Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a nonblind multicentre Korean study. Clin Drug Invest 2004;24:41-7.
8. Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int 2006;97 Suppl 2:34-8.
9. Giuliano F. Lower urinary tract symptoms and sexual dysfunction: a common approach. BJU Int 2008;101 Suppl 3:22-6.
10. Kim JH, Park JY, Oh MM, Lee JG, Kwon SS, Bae JH. Treatment satisfaction with low-dose tamsulosin for symptomatic benign prostatic hyperplasia: results from a multicentre cross-sectional survey. Int J Clin Pract 2012;66:1209-15.
11. Lee HS, Kim SW, Oh SJ, Choo MS, Lee KS. Efficacy and safety of tamsulosin for treating lower urinary tract symptoms associated with benign prostatic hyperplasia: a multicenter, randomized, controlled, open-label non-inferiority study. Korean J Urol 2012;53:178-83.
12. Zhang K, Wu W, Jin J, Ye H, Wang X, Zhang N, et al. Effect of doxazosin gastrointestinal therapeutic system 4 mg vs tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms: a prospective, multicenter, randomized, open, parallel study. Urology 2011;78:636-40.
13. Ren RM, Kou M, Lan X. Efficacy and safety of tamsulosin for the treatment of benign prostatic hyperplasia: a meta-analysis. Chin Med J (Engl) 2010;123:234-8.
14. Yuan J, Liu Y, Yang Z, Qin X, Yang K, Mao C. The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews. Curr Med Res Opin 2013;29:279-87.
15. Shim SR, Kim JH, Choi H, Lee WI, Kim HJ, Bae MY, et al. General effect of low-dose tamsulosin (0.2 mg) as a first-line treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia: a systematic review and meta-analysis. Curr Med Res Opin 2015;31:353-65.
16. Jonathan JD, Julian PT, Douglas GA. The Cochrane Collaboration: Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.0. Available at: http://www.cochrane-handbook.org.
17. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
19. Cooper HM, Hedges LV, Valentine JC. The handbook of research synthesis and meta-analysis. 2nd ed. New York: Russell Sage Foundation; 2009.
20. Gotoh M, Kamihira O, Kinukawa T, Ono Y, Ohshima S, Orihasha H; Tokai Urological Clinical Trial Group. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. BJU Int 2005;96:581-6.
21. Hanu Y, Hatano A, Nishiyama T, Obara K, Takahashi K. [A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia]. Hinyokika Kiyo 2010;56:489-94.
22. Ju XB, Wu HF, Su JT. [The clinical efficacy of Naftopidil tablet in the treatment of benign prostatic hyperplasia]. Zhonghua Nan Ke Xue 2002;2:266-8.
23. Kawabe K, Yoshida M, Homma Y; Silodosin Clinical Study Group. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III ran-
domized, placebo-controlled, double-blind study in Japanese men. BJU Int 2006;98:1019-24.
24. Masumori N, Tsukamoto T, Iwasawa A, Furuya R, Sonoda T, Mori M; Hokkaido Urological Disorders Conference Writing Group. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urol Int 2009;83:49-58.
25. Okada H, Kamidono S, Yoshioka T, Okuyama A, Ozono S, Hirao Y, et al. A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. BJU Int 2000;85:676-81.
26. Yu HJ, Lin AF, Yang SS, Tsui KH, Wu HC, Cheng CL, et al. Non-Inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). BJU Int 2011;108:1843-8.
27. Kaplan SA, Goluboff ET, Olsson CA, Deverka PA, Chmiel JJ. Effect of demographic factors, urinary peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia. Urol Int 1995;45:398-405.
28. Lepor H. Alpha blockade for the treatment of benign prostatic hyperplasia. Urol Clin North Am 1995;22:375-86.
29. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:1-13.
30. Lowe FC. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther 1997;19:730-40.
31. Schulman CC, Cortviend J, Jonas U, Lock TM, Vaage S, Speakman MJ. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 1996;29:145-54.
32. Abrams P, Schulman CC, Vaage S, Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostate 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol 1995;76:325-36.
33. Chapple CR, Wyndaele JJ, Nordling J, Boemingeshaus E, Ypma AF, Abrams P. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 1996;29:153-67.
34. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 1998;51:901-6.
35. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998;51:892-900.
36. Narayan P, Evans CP, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2003;170(2 Pt 1): 498-502.
37. Debruyne FM, Van der Poel HG. Clinical experience in Europe with 1alpha-bisphosphonate. Eur Urol 1999;36 Suppl 1: 54-8.
38. Goktas S, Kibar Y, Kilic S, Topac H, Cohan H, Seckin B. Recovery of abnormal ejaculation by intermittent tamsulosin treatment. J Urol 2006;175:650-2.
39. Narugahalli KS. Abnormal ejaculation associated with tamsulosin in benign prostatic hyperplasia patients. GOKTAS S, KIBAR Y: Recovery of abnormal ejaculation by intermittent tamsulosin treatment. J. Urol. (2006) 175:650-652. Expert Opin Investig Drugs 2006;15:1635-8.
40. Barqawi AB, Myers JB, O’Donnell C, Crawford ED. The effect of alpha-blocker and 5alpha-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms. BJU Int 2007; 100:853-7.
41. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;331:897-900.
42. Ioannidis JP. Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. CMAJ 2009;181:488-93.
43. Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000;320:1574-7.
44. Kim JH, Shim SR, Lee WJ, Kim HJ, Kwon SS, Bae JH. Sociodemographic and lifestyle factors affecting the self-perception period of lower urinary tract symptoms of international prostate symptom score items. Int J Clin Pract 2012;66:1216-23.